• Nuvation Bio disclosed FDA acceptance of supplemental new drug application seeking to update US label for IBTROZI (taletrectinib) in advanced ROS1-positive non-small cell lung cancer, with agency target action date set for Jan. 4, 2027.
• Filing reflects longer follow-up from pivotal TRUST-I, TRUST-II studies, pointing to sustained patient benefit in both previously untreated, previously treated settings without detailing new safety concerns.
• Updated study results were already presented at AACR 2026.
• Move follows IBTROZI full US approval in June 2025, supporting longer-duration efficacy claims that could strengthen positioning across lines of therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuvation Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605060800PR_NEWS_USPR_____NY52067) on May 06, 2026, and is solely responsible for the information contained therein.